Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2001

View Archived Issues

First nonpeptide somatotropin sst3 antagonists reported

Genzyme acquires Novazyme Pharmaceuticals

Enrollment completed in second phase III trial of ranolazine for chronic angina

Phase I results reported for Merck KGaA's anti-EGF receptor MAb

Patient enrollment for phase I study of RIGScan CR set to begin

Colon cancer proteomics discovery partnership signed by Genomics Collaborative and ActivX

EMEA awards orphan product status to Surfaxin for MAS

Desloratadine approved in the E.U. for symptoms of chronic idiopathic urticaria

Strategy for systemic administration of Reolysin explored

Merck & Co. reports novel farnesyltransferase inhibitor with excellent cell potency

Compounds useful as cell adhesion inhibitors patented by Aventis and Genentech

Taisho identifies PGD2-like agonists potentially useful for cardiovascular disorders

PG derivatives for prevention and treatment of vascular hypertrophy described by Taisho

NK1 antagonists useful for treating asthma and allergic rhinitis reported by UCB

COR Therapeutics reports new selective factor Xa inhibitors

Quadruple therapy including both nelfinavir and efavirenz improves response in HIV patients

Copaxone approved by 15 European countries for the treatment of MS

Transtec receives marketing approval in Germany for the treatment of nonacute pain

FDA advisory committee recommends approval of Tracleer for PAH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...